Eyepoint Pharmaceuticals (EYPT) Receives “Buy” Rating from HC Wainwright
Eyepoint Pharmaceuticals (NASDAQ:EYPT)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a note issued to investors on Thursday, September 13th, Marketbeat Ratings reports. They currently have a $2.75 price target on the stock. HC Wainwright’s target price indicates a potential downside of 18.40% from the stock’s current price.
The analysts wrote, “We note that the next milestone for the company should be the potential approval of YUTIQ three-year treatment of posterior uveitis on or before the PDUFA date of November 5, 2018. As we roll forward our DCF analysis, our estimated market value of the firm has increased to $255M from $245M. Assuming 94.7M shares outstanding at the end of 3Q19, this translates to a per share value to approximately $2.75. Therefore, we reiterate our Buy rating and raise the 12-month price target to $2.75 from $2.50.””
A number of other brokerages have also commented on EYPT. ValuEngine raised Eyepoint Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, May 29th. Zacks Investment Research lowered Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 4th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.20.
Eyepoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Wednesday, September 12th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.08). The firm had revenue of $0.72 million for the quarter, compared to analysts’ expectations of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. On average, equities analysts forecast that Eyepoint Pharmaceuticals will post -0.42 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of EYPT. Essex Investment Management Co. LLC bought a new position in shares of Eyepoint Pharmaceuticals during the 2nd quarter worth approximately $170,000. Creative Planning bought a new position in Eyepoint Pharmaceuticals in the 2nd quarter valued at $162,000. FineMark National Bank & Trust bought a new position in Eyepoint Pharmaceuticals in the 2nd quarter valued at $118,000. BlackRock Inc. bought a new position in Eyepoint Pharmaceuticals in the 2nd quarter valued at $304,000. Finally, Renaissance Technologies LLC bought a new position in Eyepoint Pharmaceuticals in the 2nd quarter valued at $2,339,000. Institutional investors and hedge funds own 62.93% of the company’s stock.
Eyepoint Pharmaceuticals Company Profile
EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, engages in developing and commercializing ophthalmic products in indications with high unmet medical need to help improve the lives of patients with eye disorders. The company has developed three FDA-approved sustained-release treatments in ophthalmology, including DEXYCU (dexamethasone intraocular suspension), which is administered as a single intraocular dose at the end of ocular surgery for postoperative inflammation; ILUVIEN (fluocinolone acetonide intravitreal implant), a micro-insert for diabetic macular edema; and Retisert (fluocinolone acetonide intravitreal implant) for posterior uveitis.
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.